Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777822 | 0.75 | — | — | |
| SCHEMBL5731973 | 0.75 | CNR1 (0.41) | CHRM3NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL19857578 | 0.72 | COMT (0.35) | NPC1ALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4909554 | 0.71 | CHRM2 (0.41) | KDM4EMEN1KMT2ATRPM8CHRM2 | |
| SCHEMBL8615796 | 0.69 | HSPA5 (0.34) | CHRM3CNR1CNR2 | |
| SCHEMBL6648798 | 0.69 | ESR1 (0.41) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL22071582 | 0.68 | COMT (0.35) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5164470 | 0.67 | — | — | |
| SCHEMBL12006685 | 0.67 | CNR1 (0.41) | CHRM3HPGDNPC1ALDH1A1RAB9A | |
| SCHEMBL2625504 | 0.67 | COMT (0.38) | NPC1ALDH1A1RAB9AKMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| WO-2006087147-A2 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF FIBROMYALGIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-24 | — | — | WO | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| EP-1072266-B1 | THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2005-08-24 | — | — | EP | claimed |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2004-08-19 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2002-12-12 | — | — | US | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1072266-A1 | THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-01-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222135-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | CHRM3 212/4885HPGD 480/4885KDM4E 3212/4885 |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | CHRM3 17/4885HPGD 223/4885KDM4E 1013/4885 |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | CHRM3 17/4885HPGD 223/4885KDM4E 1013/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | CHRM3 1391/4885HPGD 68/4885KDM4E 4024/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | CHRM3 267/4885HPGD 583/4885KDM4E 3327/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | CHRM3 1063/4885HPGD 134/4885KDM4E 4179/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | CHRM3 212/4885HPGD 480/4885KDM4E 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.